Pages that link to "Q52230887"

The following pages link to Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy (Q52230887):

Displaying 19 items.

• Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study (Q24563046) (← links)
• Elevated serum progesterone/ MII oocyte ratio on the day of human chorionic gonadotropin administration can predict impaired endometrial receptivity (Q33953801) (← links)
• The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action (Q34286656) (← links)
• Contraceptive applications of progesterone receptor modulators (Q37280942) (← links)
• Contraception with anti-progesterone (Q41060724) (← links)
• The Endometrial Approach in Contraception (Q41611354) (← links)
• Antiprogestin Action on the Endometrium (Q41611365) (← links)
• A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists (Q44688107) (← links)
• Endometrial effects of RU486 in primates--antiproliferative action despite signs of estrogen action and increased cyclin-B expression (Q45102546) (← links)
• Chronic low-dose antiprogestin impairs preimplantation embryogenesis, but not oocyte nuclear maturation or fertilization in rhesus monkeys (Q50683517) (← links)
• Contraceptive efficacy of daily administration of 0.5 mg mifepristone. (Q53990815) (← links)
• Clinical Pharmacokinetics of Mifepristone (Q55969259) (← links)
• Pharmacokinetics of mifepristone after low oral doses (Q71786985) (← links)
• Anti-implantation activity of luteal phase mifepristone administration is not mimicked by prostaglandin synthesis inhibitor or prostaglandin analogue in the rhesus monkey (Q73157741) (← links)
• Endometrial integrin expression is independent of estrogen or progestin treatment in vitro (Q73296579) (← links)
• Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea (Q74561304) (← links)
• Summary of evidence and research needs on the use of mifepristone in fertility regulation: consensus from the conference (Q75211935) (← links)
• Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers (Q77320734) (← links)
• Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats (Q77415083) (← links)